The European Commission (EC) has approved a new Opdivo (nivolumab) formulation associated with a new route of administration ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

New formulation supports adaptable care delivery in oncology settings with limited capacity or remote patient populations ...

Bristol Myers BMY announced that the European Commission (EC) has approved the subcutaneous formulation of Opdivo (nivolumab) ...

Carfilzomib-based induction/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in high-risk patients. This ...

Subcutaneous fat is the fat you can "pinch." Found throughout the body just beneath your skin, subcutaneous fat plays an important role in protecting your health, but having too much can put you ...

An oncology nurse shares advice for avoiding exhaustion and soreness when administering subcutaneous injections.

Subcutaneous Opdivo showed similar efficacy and safety to intravenous Opdivo in advanced ccRCC, with a slightly higher overall response rate. The CheckMate-67T trial confirmed pharmacokinetic and ...

The study met its primary endpoints, demonstrating noninferior pharmacokinetics (PK) for subcutaneous pembrolizumab administered with chemotherapy with a median injection time of two minutes ...